Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
Peptide manufacturing vertical on track to begin generating revenue in August 2026; VectorMist™ 510(k) submission advancing toward FDA filingMEQUON, Wis.,...